Who owns Cytomx Therapeutics?
- Ticker: CTMX
- CUSIP Number: 23284f105
Tip: Access positions for across all investors
Analyze quarterly positions in Cytomx Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Cytomx Therapeutics stock
Who bought or sold Cytomx Therapeutics this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
BVF | 6.6M | $14M | 0% | Mar 2024 |
|
Tang Capital Management | 6.5M | $14M | -2% | Mar 2024 |
|
Vanguard Group | 4.9M | $11M | -1% | Mar 2024 |
|
OrbiMed Advisors | 3.5M | $7.7M | 100% | Mar 2024 |
|
Acadian Asset Management | 2.7M | $5.9M | 2% | Mar 2024 |
|
Adage Capital Partners GP | 2.0M | $4.4M | 100% | Mar 2024 |
|
Sio Capital Management | 1.6M | $3.5M | 100% | Mar 2024 |
|
Schonfeld Strategic Advisors | 1.3M | $2.8M | 100% | Mar 2024 |
|
BlackRock | 1.1M | $2.5M | -1% | Mar 2024 |
|
Susquehanna International | 986k | $2.1M | 1013% | Mar 2024 |
|
Bronte Capital Management Pty | 906k | $2.0M | -1% | Mar 2024 |
|
Morgan Stanley | 856k | $1.9M | 1245% | Mar 2024 |
|
Laurion Capital Management | 764k | $1.7M | -30% | Mar 2024 |
|
Geode Capital Management | 753k | $1.6M | 11% | Mar 2024 |
|
Superstring Capital Management | 679k | $1.5M | 100% | Mar 2024 |
|
Millennium Management | 672k | $1.5M | -15% | Mar 2024 |
|
Jacobs Levy Equity Management | 530k | $1.2M | -33% | Mar 2024 |
|
Bridgeway Capital Management | 443k | $966k | 19% | Mar 2024 |
|
Assenagon Asset Management | 405k | $882k | 0% | Mar 2024 |
|
Connor, Clark & Lunn Investment Management | 304k | $663k | 55% | Mar 2024 |
|
Goldman Sachs Group | 294k | $641k | 100% | Mar 2024 |
|
BBK Capital Partners | 288k | $628k | -6% | Mar 2024 |
|
Toroso Investments | 288k | $631k | -6% | Mar 2024 |
|
Squarepoint Ops | 257k | $561k | 71% | Mar 2024 |
|
Two Sigma Investments | 254k | $553k | 1695% | Mar 2024 |
|
Bank of New York Mellon | 242k | $528k | -9% | Mar 2024 |
|
Congress Park Capital | 234k | $510k | -2% | Mar 2024 |
|
Clearline Capital | 197k | $429k | 0% | Mar 2024 |
|
Man Group | 191k | $417k | 100% | Mar 2024 |
|
Jane Street | 184k | $401k | 528% | Mar 2024 |
|
FMR | 183k | $399k | -74% | Mar 2024 |
|
ADAR1 Capital Management | 155k | $338k | 100% | Mar 2024 |
|
GSA Capital Partners | 149k | $324k | 43% | Mar 2024 |
|
Two Sigma Advisers | 147k | $320k | 256% | Mar 2024 |
|
Northern Trust | 134k | $292k | 12% | Mar 2024 |
|
Qube Research & Technologies | 133k | $290k | 51328% | Mar 2024 |
|
Citigroup | 124k | $270k | 100% | Mar 2024 |
|
Bank Of Montreal | 108k | $238k | 51% | Mar 2024 |
|
LPL Financial | 92k | $201k | -12% | Mar 2024 |
|
Point72 Asia | 87k | $190k | 100% | Mar 2024 |
|
Walleye Trading Advisors | 86k | $187k | 100% | Mar 2024 |
|
CornerCap Investment Counsel | 81k | $177k | 0% | Mar 2024 |
|
Bank of America Corporation | 78k | $170k | 338% | Mar 2024 |
|
Private Advisor | 69k | $151k | -5% | Mar 2024 |
|
Susquehanna Fundamental Investments | 57k | $124k | 100% | Mar 2024 |
|
Y-Intercept | 56k | $121k | 100% | Mar 2024 |
|
Commonwealth Equity Services | 53k | $116k | 0% | Mar 2024 |
|
Marshall Wace | 52k | $114k | -86% | Mar 2024 |
|
Citadel Advisors | 50k | $109k | -82% | Mar 2024 |
|
Tudor Investment Corporation | 44k | $96k | -2% | Mar 2024 |
|
Russell Investments | 43k | $93k | 3% | Mar 2024 |
|
Cubist Systematic Strategies | 42k | $91k | 100% | Mar 2024 |
|
Balyasny Asset Management | 32k | $70k | 100% | Mar 2024 |
|
SG Americas Securities | 26k | $57k | 100% | Mar 2024 |
|
Charles Schwab Investment Management | 25k | $54k | 0% | Mar 2024 |
|
Forefront Analytics | 21k | $46k | -58% | Mar 2024 |
|
UBS Group | 21k | $45k | 2% | Mar 2024 |
|
CTC Alternative Strategies | 19k | $41k | 100% | Mar 2024 |
|
LMR Partners | 18k | $40k | 100% | Mar 2024 |
|
Mackenzie Financial | 18k | $40k | -8% | Mar 2024 |
|
Brevan Howard Capital Management | 18k | $39k | 100% | Mar 2024 |
|
Taddei, Ludwig & Associates | 17k | $37k | 0% | Mar 2024 |
|
Hrt Financial | 17k | $36k | 100% | Mar 2024 |
|
XTX Topco | 13k | $27k | 100% | Mar 2024 |
|
IPG Investment Advisors | 13k | $19k | 100% | Dec 2023 |
|
ExodusPoint Capital Management | 11k | $24k | 100% | Mar 2024 |
|
D. E. Shaw & Co | 11k | $24k | -7% | Mar 2024 |
|
Vontobel Holding | 10k | $22k | 0% | Mar 2024 |
|
Whittier Trust | 6.6k | $14k | 0% | Mar 2024 |
|
Simplex Trading | 6.1k | $13k | 100% | Mar 2024 |
|
Federated Investors | 3.5k | $5.4k | 146% | Dec 2023 |
|
Rhumbline Advisers | 1.3k | $2.8k | 0% | Mar 2024 |
|
Lazard Asset Management | 1.3k | $1.0k | 100% | Dec 2023 |
|
Bollard | 712.00 | $2.0k | 0% | Mar 2024 |
|
Group One Trading | 637.00 | $1.4k | 0% | Mar 2024 |
|
Wells Fargo & Company | 524.00 | $1.1k | 2% | Mar 2024 |
|
Jpmorgan Chase & Co | 281.00 | $613.001500 | 0% | Mar 2024 |
|
Raleigh Capital Management | 250.00 | $545.000000 | 0% | Mar 2024 |
|
Old Point Trust & Financial Services N A | 250.00 | $545.000000 | 100% | Mar 2024 |
|
Bnp Paribas Arbitrage, Snc | 78.00 | $170.001000 | 0% | Mar 2024 |
|
Who sold out of Cytomx Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Franklin Resources | Dec 2023 | 27k | $42k |
AlphaMark Advisors | Dec 2023 | 23k | $36k |
Tower Research Capital | Sep 2023 | 8.2k | $11k |
Byrne Asset Management | Dec 2023 | 8.0k | $12k |
Cutler | Dec 2023 | 1.0k | $1.0k |
Royal Bank of Canada | Dec 2023 | 798.00 | $1.6k |
Advisory Services Network | Dec 2023 | 274.00 | $425.001400 |